ACADIA Pharmaceuticals Inc. (ACAD) Scheduled to Post Earnings on Wednesday
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, August 2nd. Analysts expect ACADIA Pharmaceuticals to post earnings of ($0.72) per share for the quarter.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.01. The business had revenue of $15.30 million during the quarter, compared to analyst estimates of $15.17 million. ACADIA Pharmaceuticals had a negative net margin of 948.93% and a negative return on equity of 63.07%. During the same quarter in the prior year, the firm earned ($0.45) earnings per share. On average, analysts expect ACADIA Pharmaceuticals to post $-2.82 EPS for the current fiscal year and $-2.05 EPS for the next fiscal year.
ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) opened at 30.03 on Wednesday. ACADIA Pharmaceuticals Inc. has a 52-week low of $20.68 and a 52-week high of $40.83. The stock’s 50 day moving average is $28.13 and its 200 day moving average is $32.16. The company’s market cap is $3.67 billion.
ACAD has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $49.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, April 5th. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Tuesday, July 11th. Rodman & Renshaw reiterated a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $47.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, April 12th. Finally, HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the stock. ACADIA Pharmaceuticals has a consensus rating of “Hold” and an average target price of $42.14.
ILLEGAL ACTIVITY NOTICE: “ACADIA Pharmaceuticals Inc. (ACAD) Scheduled to Post Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/26/acadia-pharmaceuticals-inc-acad-scheduled-to-post-earnings-on-wednesday.html.
In other news, EVP Glenn Baity sold 1,903 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $30.00, for a total value of $57,090.00. Following the completion of the sale, the executive vice president now directly owns 83,059 shares in the company, valued at $2,491,770. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 22.25% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.